Fig. 1 · Structure

Documents & Downloads

SBI-0206965

Cat. No. A15795 CAS 1884220-36-3

ULK1 inhibitor

SBI-0206965 is a potent, selective and cell permeable autophagy kinase ULK1 inhibitor with IC50 of 108 nM for ULK1 kinase activity and 711 nM for the highly related kinase ULK2 .

In Stock

Publications for SBI-0206965

2 publications citing this product

  1. SR Bonam, .et al. , Cells, 2020, May; 9(5): 1321 PMID: 32466347
  2. Altea Rocchi, .et al. , PLoS Genet, 2017, Aug; 13(8): e1006962 PMID: 28806762

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

SBI-0206965 inhibits ULK1 and ULK2, with reported biochemical IC50 values of 108 nM and 711 nM, respectively, in assays containing 30 μM ATP. In transfected HEK-293T cells, 10 μM treatment for 1 h reduced ULK1-associated phosphorylation of Vps34 Ser249 and Beclin1 Ser15. These cellular readouts used overexpressed proteins. [1]

SBI-0206965 also inhibits AMPK and other kinases. In an expanded kinase-profile study, MLK1 and NUAK1 had lower IC50 values than AMPK under the same 20 μM ATP condition. The compound should therefore be interpreted as a multi-target kinase tool; cellular responses alone do not establish selective ULK1 inhibition. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
ULK1 IC50 108 nM
ULK2 IC50 711 nM

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 6.78 μM Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay [PMID: 32961380]
HL-60 IC50 18.92 μM Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 24 hrs by MTT assay [PMID: 32961380]
MCF7 IC50 26.17 μM Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability after 24 hrs by MTT assay [PMID: 32961380]
MDA-MB-468 IC50 18.38 μM Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability after 24 hrs by MTT assay [PMID: 32961380]
MDA-MB-468 IC50 2.1 μM Cytotoxicity against human MDA-MB-468 cells measured after 72 hrs by Celltiter-Glo assay [PMID: 33200929]
U-937 IC50 25.12 μM Antiproliferative activity against human U937 cells assessed as reduction in cell viability after 24 hrs by MTT assay [PMID: 32961380]

SBI-0206965 Research Summary

This section summarizes 4 in vitro studies and 2 in vivo studies of SBI-0206965 from 4 published references. In vitro models include freshly isolated rat primary adipocytes.

SBI-0206965 In Vitro Studies

In rat primary adipocytes, SBI-0206965 reduced basal and insulin-stimulated glucose uptake without detectable suppression of Akt, AS160 or GSK3α/β phosphorylation. This dissociation limits attribution of metabolic effects to a single kinase pathway. [2]

ULK1 and ULK2 enzyme inhibition

Biochemical assay · Wild-type ULK1 and ULK2; cell-free radiometric kinase assays [1]

SBI-0206965 inhibited both ULK isoforms, with lower reported IC50 for ULK1. These are assay potencies rather than cellular treatment concentrations.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ULK1 kinase activityIC50 108 nM[1]
ULK2 kinase activityIC50 711 nM[1]

Literature-Reported Treatment Conditions

Method
Radiometric kinase assay; 10 μM myelin basic protein (MBP), 30 μM γ-32P-ATP; triplicate dose-response assays.
Reported limits
Enzyme amount, incubation duration and assay vehicle are not given in the read main-text caption. Supplement was not retrieved as a PDF. The caption reports a 1 μM starting concentration, while the displayed concentration axis extends higher; no exact tested series is reconstructed.
Methods and source locations

Compound reported in the paper: SBI-0206965; Compound label in the paper: 6965

Results apply to the named research compound in the reported model and conditions.

Figure 4A-B; Results: Identification and characterization of a small molecule inhibitor of ULK1

ULK1 kinase activity: Printed IC50 in Figure 4B; triplicate radiometric dose response. — Figure 4B left and caption

ULK2 kinase activity: Printed IC50 in Figure 4B; triplicate radiometric dose response. — Figure 4B right and caption

Suppression of ULK1 substrate phosphorylation

Cell-based study · HEK-293T cells overexpressing wild-type or kinase-inactive ULK1 with Flag-Vps34 or Flag-Beclin1 [1]

At 10 μM for 1 h, SBI-0206965 reduced ULK1-associated Vps34 Ser249 and Beclin1 Ser15 phosphorylation relative to vehicle. Kinase-inactive ULK1 and substrate/kinase expression blots provided controls. The authors state the phosphosite antibodies were insufficiently sensitive for endogenous proteins in total lysates.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Vps34 Ser249 and Beclin1 Ser15 phosphorylationQualitative immunoblot response Reduced relative to DMSO with wild-type ULK1[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
1 h; treatment 24 h after transfection
Method
Immunoblotting for phospho-substrates and tagged total substrate/ULK1.
Vehicle
DMSO
Reported limits
Vehicle percentage and biological replicate count are not specified for Figure 4D in the read main text. Overexpression readouts do not establish endogenous or exclusively ULK1-dependent cellular action.
Methods and source locations

Compound reported in the paper: SBI-0206965; Compound label in the paper: 6965

Results apply to the named research compound in the reported model and conditions.

Figure 4D image/caption; associated Results; Experimental Procedures: Antibodies and reagents

Vps34 Ser249 and Beclin1 Ser15 phosphorylation: Phosphosite immunoblots with total tagged substrate/ULK1 and kinase-inactive ULK1 controls; no densitometric percentage inferred. — Figure 4D; Results paragraph immediately preceding Figure 4

Expanded kinase profiling identifies off-target potency

Biochemical assay · Activity-based panel of 140 human protein kinases; selected kinase concentration-response assays [2]

The 1 μM screen (n = 2 per kinase, with/without inhibitor) and follow-up dose responses showed that SBI-0206965 inhibits MLK1 and NUAK1 more potently than AMPK under the reported 20 μM ATP condition. This limits claims of ULK1 or AMPK selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MLK1 kinase activity at 20 μM ATPIC50 (mean ± SEM) 0.071 ± 0.0015 μM[2]
NUAK1 kinase activity at 20 μM ATPIC50 (mean ± SEM) 0.087 ± 0.0015 μM[2]
AMPK kinase activity at 20 μM ATPIC50 (mean ± SEM) 0.170 ± 0.0011 μM[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM for 140-kinase screen; ten concentrations for selected IC50 assays
Exposure duration
30 min for panel assays; Lck and PBK: 15 min
Method
Cell-free γ-33P-ATP incorporation; panel ATP 5, 20 or 50 μM depending on enzyme; selected IC50 values below at 20 μM ATP.
Reported limits
The panel does not cover the whole kinome. Figure 5D values are means ± SEM; the caption does not specify a separate IC50 replicate count. Screen n = 2 must not be reassigned to IC50 fitting.
Methods and source locations

Compound reported in the paper: SBI-0206965

Results apply to the named research compound in the reported model and conditions.

Figure 5A-D; Materials and methods: kinase profiling; Results on expanded kinase panel

MLK1 kinase activity at 20 μM ATP: Ten-concentration activity assay; numerical values printed in Figure 5D table. — Figure 5D table; kinase-panel methods

NUAK1 kinase activity at 20 μM ATP: Ten-concentration activity assay; numerical values printed in Figure 5D table. — Figure 5D table; kinase-panel methods

AMPK kinase activity at 20 μM ATP: Ten-concentration activity assay; numerical values printed in Figure 5D table. — Figure 5D table; kinase-panel methods

Glucose uptake inhibition without matching insulin-signalling suppression

Cell-based study · Freshly isolated rat primary adipocytes [2]

SBI-0206965 reduced both basal and insulin-stimulated glucose uptake across the concentration series, while phosphorylation of Akt and its substrates AS160 and GSK3α/β was not detectably suppressed. The transport phenotype therefore cannot be assigned solely to inhibition of AMPK or ULK1.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Basal and insulin-stimulated glucose uptakeQualitative concentration response Both reduced as SBI-0206965 concentration increased; n = 4 per treatment, mean ± SEM[2]
Akt, AS160 and GSK3α/β phosphorylationQualitative immunoblot response No detectable suppression in primary adipocytes[2]

Literature-Reported Treatment Conditions

Treatment concentration
SBI-0206965: 10, 25, 50, 100 μM; insulin: 10 nM
Exposure duration
30 min inhibitor preincubation, then 30 min insulin; uptake measured over an additional 30 min
Method
[14C]-glucose uptake and immunoblotting; uptake and signalling are matched model readouts, not separate studies.
Vehicle
0.1% DMSO
Co-treatment
Basal and insulin-stimulated conditions evaluated separately.
Reported limits
n = 4 per treatment, mean ± SEM. Figure 3D indicates P < 0.05 comparisons as specified in its legend; no exact uptake values or inhibition percentages inferred from bars.
Methods and source locations

Compound reported in the paper: SBI-0206965

Results apply to the named research compound in the reported model and conditions.

Figure 3D-E; rat primary adipocyte methods; Results: inhibition of insulin-stimulated glucose uptake

Basal and insulin-stimulated glucose uptake: [14C]-glucose uptake; vehicle and insulin-alone comparisons. — Figure 3D and caption; rat primary adipocyte glucose-uptake methods

Akt, AS160 and GSK3α/β phosphorylation: Phosphosite and corresponding total-protein blots. — Figure 3E; associated Results paragraph

SBI-0206965 In Vivo Studies

In male Sprague-Dawley rats given 25 mg/kg intraperitoneally, SBI-0206965 reached a brain extracellular-fluid Cmax of 358.33 ± 205.39 ng/mL (mean ± SD). Plasma elimination was rapid, and oral exposure gave a relative bioavailability of 0.15 compared with intraperitoneal dosing. This study measured exposure rather than antitumor efficacy. [3]

In six-month-old 5XFAD Becn1 F121A/F121A mice, SBI-0206965 at 2 mg/kg intraperitoneally once daily for 7 days increased brain Aβ42 relative to vehicle. This reversed the reduced amyloid signal associated with the autophagy-active Becn1 mutation; it does not support a cognitive benefit from SBI-0206965. [4]

Brain exposure and limited relative oral availability

Animal study · Male Sprague-Dawley rats, 200–250 g, 6–7 weeks; brain extracellular fluid and plasma pharmacokinetics [3]

Following 25 mg/kg intraperitoneal SBI-0206965, drug was detected in brain extracellular fluid. Table 1 reports short plasma half-lives and an oral-to-intraperitoneal relative bioavailability of 0.15. These are exposure data, without tumor efficacy or absolute oral bioavailability determination.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Rat brain extracellular-fluid maximum concentration after 25 mg/kg i.p.Cmax (mean ± SD) 358.33 ± 205.39 ng/mL[3]
Rat plasma elimination half-lifet1/2 (mean ± SD) i.p.: 1.06 ± 0.70 h; oral: 1.08 ± 0.16 h[3]
Relative oral availability referenced to intraperitoneal administrationRelative F 0.15[3]

Conditions shared by the study groups

Frequency
Single administration
Treatment course
Single-dose PK
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Rat intraperitoneal exposure
25 mg/kg
Plasma and brain ECF compared; oral arm is a route comparator.Brain ECF Cmax 358.33 ± 205.39 ng/mL; plasma half-life 1.06 ± 0.70 h.[3]
Rat oral exposure
25 mg/kg
Intraperitoneal arm, same reported dose.Plasma half-life 1.08 ± 0.16 h; relative oral bioavailability 0.15 vs i.p.[3]
Rat intraperitoneal exposure
Model: Male Sprague-Dawley rats; N = 5
Route: Intraperitoneal
Reported limits: Rat formulation not stated in read main text. Peak time and sampling schedule excluded due to internal discrepancies.
Rat oral exposure
Model: Male Sprague-Dawley rats; N = 4
Route: Oral
Reported limits: Rat oral formulation and exact administration technique are not specified in the read main text.
Methods and source locations

Compound reported in the paper: SBI-0206965

Results apply to the named research compound in the reported model and conditions.

Figure 1A-B; Table 1; rat microdialysis, drug administration, bioanalysis and statistical-analysis methods; BBB/systemic PK Results

Rat brain extracellular-fluid maximum concentration after 25 mg/kg i.p.: Table 1 non-compartmental parameters; Figure 1A caption N = 5. — Table 1: Cmax row, Brain ECF (i.p.) column; Figure 1A caption

Rat plasma elimination half-life: Table 1; Figure 1 caption: i.p. N = 5, oral N = 4. — Table 1: T1/2 row; Figure 1B caption

Relative oral availability referenced to intraperitoneal administration: Comparison of oral and i.p. plasma AUC; no i.v. arm, not absolute bioavailability. — Table 1 final row; BBB/systemic PK Results

Rat intraperitoneal exposure · Figure 1A-B captions; Table 1; Drug administration and sampling protocol

Rat oral exposure · Figure 1B caption; Table 1; BBB/systemic PK Results

SBI-0206965 reverses reduced brain Aβ42 in an autophagy-active mouse model

Animal study · Six-month-old 5XFAD Becn1 F121A/F121A mice (Becn1 FA/FA); C57BL/6 background [4]

Seven days of SBI-0206965 increased total brain Aβ42 relative to vehicle, reversing the reduction associated with the autophagy-active Becn1 mutation. This inhibitor-control experiment is a limiting result; it does not show cognitive benefit from SBI-0206965 or establish exclusive ULK1 mediation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Total brain Aβ42 immunoreactivityQualitative increase; reported significance Increased vs vehicle; N = 5; mean ± SEM; P < 0.01[4]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Once daily
Treatment course
7 days; tissues collected 4 h after final injection
Vehicle
PBS containing 50% DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
SBI-0206965 treatment
2 mg/kg body weight
Vehicle-treated mice of the same 5XFAD Becn1 FA/FA model; Ponceau S loading control.Increased total brain Aβ42 vs vehicle (P < 0.01).[4]
SBI-0206965 treatment
Model: Six-month-old 5XFAD Becn1 FA/FA mice; Figure 3E N = 5
Reported limits: Sex for this cohort and randomization/blinding are not specified in the read relevant text; exact effect size not tabulated.
Methods and source locations

Compound reported in the paper: SBI-0206965

Results apply to the named research compound in the reported model and conditions.

Figure 3E image/caption; Results: Becn1 F121A decreases amyloid accumulation; Methods: Drug treatment, Dot blot assay, Statistical analyses

Total brain Aβ42 immunoreactivity: Aβ42 dot blot normalized to Ponceau S; two-tailed unpaired Student’s t-test in Statistical analyses. — Figure 3E image and caption; Dot blot assay; Statistical analyses

SBI-0206965 treatment · Figure 3E and caption; Methods: Drug treatment, Dot blot assay, Statistical analyses

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1884220-36-3
Applications ULK1 inhibitor
Formula C21H21BrN4O5
Molecular Weight 489.32
SMILES
CNC(=O)C1=CC=CC=C1OC2=NC(=NC=C2Br)NC3=CC(=C(C(=C3)OC)OC)OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 90 mg/mL (183.92 mM)
Water Insoluble
Ethanol Warmed: 9 mg/mL (18.39 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

SBI-0206965 Research References

  1. [1] Daniel F Egan, Matthew GH Chun, Mitchell Vamos, et al. Small molecule inhibition of the autophagy kinase ULK1 and identification of ULK1 substrates Molecular Cell (2015). PMID: 26118643 DOI: 10.1016/j.molcel.2015.05.031 Source material
  2. [2] Danial Ahwazi, Katyayanee Neopane, Greg R Markby, et al. Investigation of the specificity and mechanism of action of the ULK1/AMPK inhibitor SBI-0206965 Biochemical Journal (2021). PMID: 34259310 DOI: 10.1042/BCJ20210284 Source material
  3. [3] Janki M Desai, Aniruddha S Karve, Gary A Gudelsky, et al. Brain pharmacokinetics and metabolism of the AMP-activated protein kinase selective inhibitor SBI-0206965, an investigational agent for the treatment of glioblastoma Investigational New Drugs (2022). PMID: 35802287 DOI: 10.1007/s10637-022-01278-8 Source material
  4. [4] Altea Rocchi, Soh Yamamoto, Tabitha Ting, et al. A Becn1 mutation mediates hyperactive autophagic sequestration of amyloid oligomers and improved cognition in Alzheimer's disease PLOS Genetics (2017). PMID: 28806762 DOI: 10.1371/journal.pgen.1006962 Source material

Publications

2 publications citing this product

  1. SR Bonam, .et al. , Cells, 2020, May; 9(5): 1321 PMID: 32466347
  2. Altea Rocchi, .et al. , PLoS Genet, 2017, Aug; 13(8): e1006962 PMID: 28806762

Added to your cart

View Cart Checkout
Loading...